Clinical reference Biomarker Directory
Back to directory

MAPT

Emerging

MAPT/tau blood biomarkers (p-tau217, p-tau181) are central to modern Alzheimer's diagnosis and anti-amyloid treatment monitoring.

Also known as Tau MAPT microtubule-associated protein tau
In plain language

MAPT makes tau protein, which builds up abnormally in Alzheimer's disease. Blood tests for specific tau forms are now central to diagnosing and monitoring the disease, especially for patients on the newest Alzheimer's drugs, and may even show early signs of the disease returning faster than brain scans do.

Biomarker & context

MAPT encodes tau protein, whose pathological aggregation (as phosphorylated tau, or p-tau) is a defining feature of Alzheimer's disease and other tauopathies.

What it indicates

Blood p-tau217 and p-tau181 are now central to modern Alzheimer's disease diagnostic pathways, alongside amyloid beta42 (discussed elsewhere in this set); elevated levels support a biological Alzheimer's diagnosis even before significant cognitive symptoms in some frameworks.

Diagnosis & clinical testing

Current lecanemab-era practice increasingly uses these blood tests to confirm amyloid/tau pathology before starting or monitoring anti-amyloid antibody treatment, watching for reductions in p-tau181/217 as a marker of treatment response, per the 2024 Alzheimer's Association revised diagnostic criteria.

Guiding treatment

After discontinuation of lecanemab, increases in p-tau181 concentrations were observed more quickly than changes seen on amyloid PET imaging, suggesting blood tau markers may offer an earlier signal of disease reactivation than imaging alone, though more research is needed before this guides individual treatment-restart decisions.

Clinical significance

May offer an earlier signal of disease reactivation after treatment discontinuation than amyloid PET imaging.

References
  1. PMC. (2025). Tau biology, biomarkers, and therapeutics.
  2. PMC. (2025). The Biomarker Profile of Alzheimer's Disease for Disease-Modifying Treatment Eligibility.